Bleselumab
Based on 1 Customer Validation
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.97%
- CAS No.: 1453067-91-8
- Masse moléculaire:144.6 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFRSF5/CD40
In Vitro
Bleselumab (0-1 μg/mL, 48 h) dose-depently inhibits PBMCs proliferation induced by soluble CD154[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PBMCs
-
Concentration:0-1 μg/mL
-
Incubation Time:48 h
-
Result:Inhibited PBMC proliferation induced by shCD154 in human, cynomolgus monkey and rabbit blood samples.
In Vivo
Bleselumab (2 mg/kg, i.v.) prolongs renal allograft survival in Cynomolgus monkeys[3].
Bleselumab (2 or 5 mg/kg, i.v.) together with Tacrolimus (HY-13756) shows a longer median survival time (MST) than monotherapy[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys[2].
-
Dosage:0.1, 1 and 10 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:Inhibited anti-TTx IgG and anti-TTx IgM productions in a concentration-dependent manner.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling TNFRSF5/CD40 (red) with Bleselumab (anti-TNFRSF5/CD40) (HY-P99257). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1453067-91-8
-
Appearance Liquid
-
Masse moléculaire 144.6 kDa
-
Color Colorless to light yellow
-
SMILES
[Bleselumab]
-
Synonyms
ASKP 1240
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171. [Content Brief]
[2]. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9. [Content Brief]
[3]. Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bleselumab Related Classifications
HY-P99257 Related Classifications
Powered by Bioz